Blockchain Registration Transaction Record

Clene Announces Significant Updates to ACT-EAP for CNM-Au8 Compassionate Use in ALS

Clene announces significant updates to their ACT-EAP for CNM-Au8 compassionate use in ALS, expanding the program's capacity to accommodate up to 180 participants. This collaboration addresses the crucial need for accessible treatment programs for ALS, a fatal neurodegenerative disease with no known cure.

This news matters because it highlights the efforts of Clene to expand access to treatment programs for ALS, a fatal neurodegenerative disease with no known cure. The collaboration with Columbia University and Synapticure, funded by the ACT for ALS Act, demonstrates the commitment to addressing the crucial need for accessible therapies. The expansion of the program's capacity to accommodate up to 180 participants is a significant step in improving the quality of life for ALS patients.